The ODPRN has conducted multiple studies evaluating drug policy and effectiveness which have impacted societal outcomes and improved healthcare system efficiency. This research includes a wide breadth of work ranging from large drug class reviews to specific rapid responses resulting from decision makers’ pressing initiatives.
For most patients with diabetes, routine use of blood glucose test strips (BGTS) has not been shown to be beneficial, yet the economic implications of broad publicly funded reimbursement for BGTS are substantial. We assessed the potential impact of BGTS quantity limits on utilization and costs for 6 publicly funded drug plans across Canada.
In 2013, Ontario was one of the first payers to introduce a policy limiting reimbursements for BGTS aligned with recommendations from the Canadian Diabetes Association. This study investigates the impact of this policy on patient outcomes among adults with diabetes in Ontario.
This rapid analysis reports the utilization of high strength formulations of long-acting hydromorphone, morphine and fentanyl and their usage among palliative care patients to inform discussions on reimbursement changes within the Ontario Drug Benefit (ODB) program.